Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use

被引:204
|
作者
Baggish, Aaron L. [1 ,2 ]
Weiner, Rory B. [1 ,2 ]
Kanayama, Gen [3 ,4 ,5 ]
Hudson, James I. [3 ,4 ,5 ]
Lu, Michael T. [6 ,7 ]
Hoffmann, Udo [6 ,7 ]
Pope, Harrison G., Jr. [3 ,4 ,5 ]
机构
[1] Massachusetts Gen Hosp, Div Cardiol, Cardiovasc Performance Program, Boston, MA 02114 USA
[2] Harvard Med Sch, Dept Med, Boston, MA USA
[3] McLean Hosp, Biol Psychiat Lab, 115 Mill St, Belmont, MA 02178 USA
[4] McLean Hosp, Psychiat Epidemiol Res Program, 115 Mill St, Belmont, MA 02178 USA
[5] Harvard Med Sch, Dept Psychiat, Boston, MA USA
[6] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA
[7] Harvard Med Sch, Dept Radiol, Boston, MA 02114 USA
关键词
anabolic-androgenic steroids; atherosclerosis; cardiology; cardiomyopathy; diastolic dysfunction; men; RISK-FACTORS; VENTRICULAR HYPERTROPHY; MYOCARDIAL-INFARCTION; TISSUE DOPPLER; SOCIETY; WEIGHTLIFTERS; TESTOSTERONE; CONSEQUENCES; DYSFUNCTION; PREVALENCE;
D O I
10.1161/CIRCULATIONAHA.116.026945
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Millions of individuals have used illicit anabolic-androgenic steroids (AAS), but the long-term cardiovascular associations of these drugs remain incompletely understood. METHODS: Using a cross-sectional cohort design, we recruited 140 experienced male weightlifters 34 to 54 years of age, comprising 86 men reporting >= 2 years of cumulative lifetime AAS use and 54 nonusing men. Using transthoracic echocardiography and coronary computed tomography angiography, we assessed 3 primary outcome measures: left ventricular (LV) systolic function (left ventricular ejection fraction), LV diastolic function (early relaxation velocity), and coronary atherosclerosis (coronary artery plaque volume). RESULTS: Compared with nonusers, AAS users demonstrated relatively reduced LV systolic function (mean +/- SD left ventricular ejection fraction = 52 +/- 11% versus 63 +/- 8%; P < 0.001) and diastolic function (early relaxation velocity = 9.3 +/- 2.4 cm/second versus 11.1 +/- 2.0 cm/second; P < 0.001). Users currently taking AAS at the time of evaluation (N=58) showed significantly reduced LV systolic (left ventricular ejection fraction = 49 +/- 10% versus 58 +/- 10%; P < 0.001) and diastolic function (early relaxation velocity = 8.9 +/- 2.4 cm/second versus 10.1 +/- 2.4 cm/second; P=0.035) compared with users currently off-drug (N=28). In addition, AAS users demonstrated higher coronary artery plaque volume than nonusers (median [interquartile range] 3 [0, 174] mL(3) versus 0 [0, 69] mL(3);P=0.012). Lifetime AAS dose was strongly associated with coronary atherosclerotic burden (increase [95% confidence interval] in rank of plaque volume for each 10-year increase in cumulative duration of AAS use: 0.60 SD units [0.16-1.03 SD units]; P=0.008). CONCLUSIONS: Long-term AAS use appears to be associated with myocardial dysfunction and accelerated coronary atherosclerosis. These forms of AAS-associated adverse cardiovascular phenotypes may represent a previously underrecognized public-health problem.
引用
收藏
页码:1991 / +
页数:26
相关论文
共 50 条
  • [21] Fitness Supplements as a Gateway Substance for Anabolic-Androgenic Steroid Use
    Hildebrandt, Tom
    Harty, Seth
    Langenbucher, James W.
    PSYCHOLOGY OF ADDICTIVE BEHAVIORS, 2012, 26 (04) : 955 - 962
  • [22] Psychiatric and medical effects of anabolic-androgenic steroid use in women
    Gruber, AJ
    Pope, HG
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2000, 69 (01) : 19 - 26
  • [23] Anabolic-Androgenic Steroid Use is Associated with Risk Behaviors and Psychopathy
    Nelson, Bryan S.
    Hildebrandt, Tom
    Wallisch, Pascal
    INTERNATIONAL JOURNAL OF PSYCHOLOGY, 2016, 51 : 641 - 642
  • [24] Prevalence and Correlates of Anabolic-Androgenic Steroid Use in Australian Adolescents
    Byatt, Dominic
    Bussey, Kay
    Croft, Tim
    Trompeter, Nora
    Mitchison, Deborah
    NUTRIENTS, 2025, 17 (06)
  • [25] Psychosocial correlates of gap time to anabolic-androgenic steroid use
    Klimek, Patrycja
    Hildebrandt, Tom
    INTERNATIONAL JOURNAL OF EATING DISORDERS, 2018, 51 (06) : 535 - 541
  • [26] Anabolic-androgenic steroid use among young Finnish males
    Mattila, V. M.
    Rimpela, A.
    Jormanainen, V.
    Sahi, T.
    Pihlajamaki, H.
    SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS, 2010, 20 (02) : 330 - 335
  • [27] Illicit Anabolic-Androgenic Steroid Induced Vascular Occlusions In Weightlifters: A Tale Of Two Cases
    Akkad, Ghassan
    Meller, Leo
    Huang, Brady
    Wilson, Katherine D.
    Allen, Matthew
    Vitale, Kenneth
    MEDICINE & SCIENCE IN SPORTS & EXERCISE, 2024, 56 (10) : 771 - 772
  • [28] Anabolic-androgenic steroids and cardiovascular risk
    Liu Jian-Di
    Wu Yan-Qing
    中华医学杂志英文版, 2019, 132 (18) : 2229 - 2236
  • [29] Risk Factors for Illicit Anabolic-Androgenic Steroid Use in Male Weightlifters: A Cross-Sectional Cohort Study
    Pope, Harrison G., Jr.
    Kanayama, Gen
    Hudson, James I.
    BIOLOGICAL PSYCHIATRY, 2012, 71 (03) : 254 - 261
  • [30] Anabolic-androgenic steroids and cardiovascular risk
    Liu, Jian-Di
    Wu, Yan-Qing
    CHINESE MEDICAL JOURNAL, 2019, 132 (18) : 2229 - 2236